516 related articles for article (PubMed ID: 29347944)
41. CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma.
Wang L; Gu F; Ma N; Zhang L; Bian JM; Cao HY
Tumour Biol; 2013 Aug; 34(4):2309-13. PubMed ID: 23568706
[TBL] [Abstract][Full Text] [Related]
42. [Factors influencing survival of patients with pancreatic adenocarcinoma after surgical resection].
Fang LP; Xu XY; Ji Y; Huang PW
Zhonghua Yi Xue Za Zhi; 2018 Feb; 98(8):606-611. PubMed ID: 29534390
[No Abstract] [Full Text] [Related]
43. Annexin A2 and CD105 expression in pancreatic ductal adenocarcinoma is associated with tumor recurrence and prognosis.
Huang YK; Liu H; Wang XZ; Zhu S
Asian Pac J Cancer Prev; 2014; 15(22):9921-6. PubMed ID: 25520129
[TBL] [Abstract][Full Text] [Related]
44. Clinicopathological significance of Necl-4 expression in pancreatic ductal adenocarcinoma.
Kawanishi A; Hirabayashi K; Yamada M; Takanashi Y; Hadano A; Kawaguchi Y; Nakagohri T; Nakamura N; Mine T
J Clin Pathol; 2017 Jul; 70(7):619-624. PubMed ID: 27980052
[TBL] [Abstract][Full Text] [Related]
45. Comprehensive histological evaluation with clinical analysis of venous invasion in pancreatic ductal adenocarcinoma: From histology to clinical implications.
Lee SJ; Sung YN; Kim SJ; Shin S; Cho H; Hruban RH; Hong SM
Pancreatology; 2020 Oct; 20(7):1486-1494. PubMed ID: 32948429
[TBL] [Abstract][Full Text] [Related]
46. Overexpression of sialyl Lewis x antigen is associated with formation of extratumoral venous invasion and predicts postoperative development of massive hepatic metastasis in cases with pancreatic ductal adenocarcinoma.
Takahashi S; Oda T; Hasebe T; Sasaki S; Kinoshita T; Konishi M; Ueda T; Nakahashi C; Ochiai T; Ochiai A
Pathobiology; 2001; 69(3):127-35. PubMed ID: 11872958
[TBL] [Abstract][Full Text] [Related]
47. Toll-like receptor 2 and Toll-like receptor 4 predict favorable prognosis in local pancreatic cancer.
Lanki MA; Seppänen HE; Mustonen HK; Böckelman C; Juuti AT; Hagström JK; Haglund CH
Tumour Biol; 2018 Sep; 40(9):1010428318801188. PubMed ID: 30246618
[TBL] [Abstract][Full Text] [Related]
48. High calpain-1 expression predicts a poor clinical outcome and contributes to tumor progression in pancreatic cancer patients.
Yu LM; Zhu YS; Xu CZ; Zhou LL; Xue ZX; Cai ZZ
Clin Transl Oncol; 2019 Jul; 21(7):924-932. PubMed ID: 30565085
[TBL] [Abstract][Full Text] [Related]
49. Expression of FXR and HRG and their clinicopathological significance in benign and malignant pancreatic lesions.
Chen XL; Xie KX; Yang ZL; Yuan LW
Int J Clin Exp Pathol; 2019; 12(6):2111-2120. PubMed ID: 31934033
[TBL] [Abstract][Full Text] [Related]
50. Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Yuasa Y; Sueda T
World J Surg; 2010 Aug; 34(8):1900-7. PubMed ID: 20376442
[TBL] [Abstract][Full Text] [Related]
51. The prognostic significance of clinicopathological features and apoptosis inhibitor proteins in pancreas ductal adenocarcinoma.
Argon A; Nart D; Oruç N; Coker A; Ozütemiz O
Acta Gastroenterol Belg; 2014 Jun; 77(2):229-34. PubMed ID: 25090821
[TBL] [Abstract][Full Text] [Related]
52. Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes.
Wang X; Ren H; Zhao T; Ma W; Dong J; Zhang S; Xin W; Yang S; Jia L; Hao J
Oncotarget; 2016 Mar; 7(12):13717-29. PubMed ID: 26872370
[TBL] [Abstract][Full Text] [Related]
53. [Clinical implication of BRSK2 expression in pancreatic ductal adenocarcinoma].
Niu GM; Ji Y; Jin DY; Hou J; Lou WH
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(16):1084-8. PubMed ID: 20646422
[TBL] [Abstract][Full Text] [Related]
54. Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance.
Xue YZ; Sheng YY; Liu ZL; Wei ZQ; Cao HY; Wu YM; Lu YF; Yu LH; Li JP; Li ZS
Tumour Biol; 2013 Apr; 34(2):895-9. PubMed ID: 23247867
[TBL] [Abstract][Full Text] [Related]
55. [Expression of dihydropyrimidine dehydrogenase negatively correlated with the prognosis of pancreatic ductal adenocarcinoma].
Fang Y; Ji Y; Lou WH
Zhonghua Wai Ke Za Zhi; 2011 Apr; 49(4):330-4. PubMed ID: 21612699
[TBL] [Abstract][Full Text] [Related]
56. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma.
Khan S; Zafar N; Khan SS; Setua S; Behrman SW; Stiles ZE; Yallapu MM; Sahay P; Ghimire H; Ise T; Nagata S; Wang L; Wan JY; Pradhan P; Jaggi M; Chauhan SC
HPB (Oxford); 2018 Jun; 20(6):563-572. PubMed ID: 29352660
[TBL] [Abstract][Full Text] [Related]
57. Survivin expression and serum levels in pancreatic cancer.
Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
[TBL] [Abstract][Full Text] [Related]
58. Role of the lymph node ratio in pancreatic ductal adenocarcinoma. Impact on patient stratification and prognosis.
La Torre M; Cavallini M; Ramacciato G; Cosenza G; Rossi Del Monte S; Nigri G; Ferri M; Mercantini P; Ziparo V
J Surg Oncol; 2011 Nov; 104(6):629-33. PubMed ID: 21713779
[TBL] [Abstract][Full Text] [Related]
59. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
[TBL] [Abstract][Full Text] [Related]
60. Duodenal Involvement is an Independent Prognostic Factor for Patients with Surgically Resected Pancreatic Ductal Adenocarcinoma.
Dal Molin M; Blackford AL; Siddiqui A; Brant A; Cho C; Rezaee N; Yu J; He J; Weiss M; Hruban RH; Wolfgang C; Goggins M
Ann Surg Oncol; 2017 Aug; 24(8):2379-2386. PubMed ID: 28439733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
